8-K 1 shire8k.txt FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2001 Shire Pharmaceuticals Group plc -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) England and Wales -------------------------------------------------------------------------------- (State or other jurisdiction of incorporation) 0-29630 N/A ------------------------------ -------------------------------------------- (Commission File Number) (IRS Employer Identification No.) Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP England -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code 44 1256 894 000 ------------------------------ -------------------------------------------------------------------------------- (Former name or former address, if changed since last report) Item 7. Financial Statements and Exhibits (c) Exhibits. The following exhibit is filed herewith: 99.1 Presentation relating to first quarter results and BioChem Pharma, Inc. merger. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 11, 2001 SHIRE PHARMACEUTICALS GROUP PLC By: /s/ Angus C. Russell --------------------------------------- Name: Angus C. Russell Title: Group Finance Director EXHIBIT INDEX Number Description 99.1 Presentation relating to first quarter results and BioChem Pharma, Inc. merger.